Grace Therapeutics, Inc. (GRCE)
GRCE Stock Price Chart
Explore Grace Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GRCE price movements and trends.
GRCE Company Profile
Discover essential business fundamentals and corporate details for Grace Therapeutics, Inc. (GRCE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Feb 2012
Employees
4.00
Website
https://www.acastipharma.comCEO
Prashant Kohli
Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
GRCE Financial Timeline
Browse a chronological timeline of Grace Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.12.
Earnings released on 12 Aug 2025
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%.
Earnings released on 23 Jun 2025
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $8.00K .
Earnings released on 13 Feb 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%.
Earnings released on 13 Nov 2024
EPS came in at -$0.33 matching the estimated -$0.33.
Earnings released on 9 Aug 2024
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%.
Earnings released on 21 Jun 2024
EPS came in at -$0.18 surpassing the estimated -$0.35 by +48.57%.
Earnings released on 31 Dec 2023
EPS came in at -$0.21 surpassing the estimated -$0.23 by +9.65%.
Earnings released on 30 Sept 2023
EPS came in at -$0.43 falling short of the estimated -$0.26 by -66.68%.
Stock split effective on 10 Jul 2023
Shares were split 1 : 6 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2023
EPS came in at -$0.54 falling short of the estimated -$0.28 by -93.23%.
Earnings released on 31 Mar 2023
EPS came in at -$3.90 falling short of the estimated -$0.84 by -364.29%.
Earnings released on 31 Dec 2022
EPS came in at -$0.52 surpassing the estimated -$0.74 by +29.32%.
Earnings released on 30 Sept 2022
EPS came in at -$0.66 .
Earnings released on 30 Jun 2022
EPS came in at -$0.61 .
Earnings released on 31 Mar 2022
EPS came in at -$0.40 .
Earnings released on 31 Dec 2021
EPS came in at -$0.51 .
Earnings released on 30 Sept 2021
EPS came in at $0.18 .
Stock split effective on 31 Aug 2021
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2021
EPS came in at -$0.72 .
Earnings released on 31 Mar 2021
EPS came in at -$1.99 , while revenue for the quarter reached $196.00K .
Earnings released on 31 Dec 2020
EPS came in at -$1.54 , while revenue for the quarter reached $81.00K .
Earnings released on 30 Sept 2020
EPS came in at -$3.10 .
GRCE Stock Performance
Access detailed GRCE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.